Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,178.00    -4.00 (-0.18%)
Bid:
2,192.00
Ask:
2,220.00
Spread: 28.00 (1.277%)
Market Cap: £1.45b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

Interim Management Statement

11 May 2011 07:00

RNS Number : 3201G
Genus PLC
11 May 2011
 



For immediate release 11 May 2011

 

 

GENUS plc

("Genus" or "the Company")

 

Interim Management Statement

 

Genus, a leading global animal genetics company, today publishes its interim management statement for the period from 1 January 2011 to 10 May 2011.

Market Conditions

In general the markets in which the Group operates have continued to improve, despite continuing high feed costs.

Pig prices have kept pace with the increases in feed costs in most countries and, as a result, customer profitability and the demand for Genus' products have been sustained. The exception to this has been in Europe where price increases have not been sufficient to restore profitability for pig producers and so the market has been relatively soft. In China, prices started to increase following the disease outbreaks last year and this has led to improved demand for genetics.

In bovines, milk prices have risen to better levels in most markets.

Trading Performance

Based on the results for the four months to 30 April 2011, Genus has continued to perform ahead of last year and in line with the Board's expectations.

In North America, the porcine business has continued to trade well with increased royalty income. In bovine, improved average selling prices and the benefit of cost reductions implemented in the first half of the year have improved profitability on sales at a similar level to last year. Demand has remained buoyant in Latin America resulting in increased volumes in both the bovine and porcine sectors.

In Europe, bovine performance improved as sales delayed from the first half of the year came through and dairy markets firmed. Porcine performance remained weak with reduced customer demand because of poor industry profitability.

In the Far East, strong growth in bovine volumes continued. Porcine performance began to improve as customer demand in China increased following a rise in pig prices.

Good progress has continued with the initiatives aimed at ensuring emerging market growth opportunities. Work to bring the new stud in Russia up to Genus' standards is nearing completion. A further 16 bulls have been shipped to China to meet the growing demand for progeny tested semen and strong sales growth is being achieved in India.

Financial Position

Net debt at 30 April 2011 of £85.4m was below the level at the same time last year (£94.0m), reflecting the group's underlying strong cash generation. It was, however, higher than at 31 December 2010, mainly because of the payment of the annual dividend and the £7.0m cash settlement cost of a US dollar swap transaction used to hedge the Group's US dollar net asset position.

The Group completed a refinancing in March 2011 to provide £135m of facilities on an unsecured basis through to 30 September 2015.

Outlook

Genus expects to continue to make good progress for the remainder of the year and that, as a result, the full year results to June 2011 will be in line with the Board's expectations.

Genus will announce its preliminary results for the year ending 30 June 2011 on 6 September 2011.

 

For further information please contact:-

 

Genus plc Tel: 01256 345970

 

Richard Wood, Chief Executive

John Worby, Finance Director

 

Buchanan Communications Tel: 0207 466 5000

 

Charles Ryland

Suzanne Brocks

Helen Chan

 

This announcement is available on the Genus website, www.genusplc.com

 

 

 

 

About Genus:

 

Genus plays a key role in the world's agricultural economy in its creation of advances in animal breeding through naturally applied biotechnology, helping farmers and food producers across the world to improve quality and increase output.

 

Genus provides superior natural animal genetics, enabling our global customers in the bovine and porcine supply chain to produce offspring in their herds with greater production efficiency, milk and meat output and quality. The challenge of meeting growing global demand for milk, pork and beef from the decreasing resources available for food production requires innovative solutions that Genus provides.

 

Genus' worldwide sales are made in seventy countries under the trade marks "ABS" (dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animals with superior genetics to those animals currently in production.

 

Genus' competitive edge has been created from the ownership and control of proprietary lines of breeding animals and the biotechnology used to improve them. Genus' global production and distribution network underpins our unique position in the world's growing agricultural markets.

 

Headquartered in Basingstoke, England, Genus is a FTSE250 company that operates in 30 countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSSFAFLSFFSELI
Date   Source Headline
18th May 20231:32 pmRNSDirector/PDMR Shareholding
16th May 20236:16 pmRNSDirector/PDMR Shareholding
16th May 20237:00 amRNSTrading Update
9th May 20234:30 pmRNSNotification of Major Holdings
3rd May 20238:44 amRNSTotal Voting Rights
2nd May 20237:00 amRNSShare Award for Incoming CEO
3rd Apr 202311:27 amRNSTotal Voting Rights
3rd Apr 20237:00 amRNSAppointment of Chief Executive Officer Designate
21st Mar 20232:58 pmRNSApplication for Block Listing
6th Mar 202312:53 pmRNSNotification of Major Holdings
2nd Mar 20231:51 pmRNSNotification of Major Holdings
1st Mar 20232:20 pmRNSNotification of Major Holdings
24th Feb 20235:13 pmRNSDirector/PDMR Shareholding
24th Feb 202311:39 amRNSNotification of Major Holdings
23rd Feb 20239:33 amRNSReplacement: Interim Results
23rd Feb 20237:00 amRNSChief Executive Officer Retirement
23rd Feb 20237:00 amRNSInterim Results
21st Feb 20235:03 pmRNSNotification of Major Holdings
10th Feb 20232:08 pmRNSNotification of Major Holdings
1st Feb 202310:00 amRNSBlock listing Interim Review
23rd Nov 20221:02 pmRNSResult of AGM
23rd Nov 20227:00 amRNSAGM Trading Update
3rd Nov 20227:00 amRNSRuthin Site Visit
14th Oct 202211:39 amRNSTR-1: Notification of Major Holdings
14th Oct 20227:00 amRNSAnnual Report and Annual General Meeting
15th Sep 202210:55 amRNSNotification of Major Holdings
14th Sep 20224:41 pmRNSDirector/PDMR Shareholding
13th Sep 20226:08 pmRNSDirector/PDMR Shareholding
8th Sep 20221:57 pmRNSNotification of Major Holdings
8th Sep 20227:00 amRNSPreliminary Results
2nd Sep 20229:05 amRNSTotal Voting Rights
2nd Aug 20227:00 amRNSAppointment of Joint Corporate Broker
1st Aug 202210:10 amRNSBlock listing Interim Review
21st Jul 202210:21 amBUSForm 8.3 - Genus Plc - CORRECTION
21st Jul 202210:05 amRNSHolding(s) in Company
20th Jul 20223:03 pmRNSNotification of Major Holdings
19th Jul 202211:57 amBUSForm 8.3 - Genus Plc
5th Jul 20222:10 pmRNSNotification of Major Holdings
1st Jul 20229:35 amRNSTotal Voting Rights
24th Jun 20223:42 pmRNSNotification of Major Holdings
6th Jun 20229:11 amRNSNotification of Major Holdings
1st Jun 202212:45 pmRNSNotification of Major Holdings
30th May 202212:18 pmRNSNotification of Major Holdings
17th May 20229:26 amRNSNotification of Major Holdings
21st Apr 20227:00 amRNSNotification of Major Holdings
19th Apr 20221:50 pmRNSNotification of Major Holdings
31st Mar 20221:34 pmRNSDirector Declaration
28th Mar 20225:36 pmRNSNotification of Major Holdings
8th Mar 20223:47 pmRNSNotification of Major Holdings
8th Mar 20221:13 pmRNSNotification of Major Holdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.